Thymic epithelial tumors: what’s new and what’s next?

Thymic epithelial tumors (TETs) are rare malignancies originating from the thymic epithelium, characterized by heterogeneous clinical behavior and requiring a tailored approach for optimal management. Recent advancements in disease staging and treatment highlight the need for a critical reassessment of both past and current data to accurately interpret clinical evidence. The therapeutic landscape for advanced TETs has evolved beyond conventional chemotherapy, with significant progress in targeted therapies, particularly antiangiogenic agents, and immune checkpoint inhibitors. However, emerging data also underscore concerns regarding immune-related toxicities. In parallel, novel molecular insights into TETs are shaping the development of potential predictive biomarkers, which require rigorous validation before they can be integrated into clinical practice. Given the inherent challenges of conducting high-quality studies in rare tumors, such as TETs, this review discusses methodological advancements and regulatory, logistical, and organizational strategies to strengthen the robustness of clinical research in this field. By synthesizing recent progress and highlighting key areas for future investigation, this review aims to support the development of evidence-based, personalized treatment approaches and ultimately improve clinical outcomes for patients with TETs.